Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib Study of HS-10516 to Investigate the Safety, Tolerance, Pharmacokinetic and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT06049030 is registered in ClinicalTrials.gov with Jiangsu Hansoh Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06049030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06049030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib Study of HS-10516 to Investigate the Safety, Tolerance, Pharmacokinetic and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
September 25, 2023
Completion date
September 25, 2025
Enrollment
190 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma